肾细胞癌的分子靶向治疗

Molecular-based therapies for renal cell carcinoma.

作者信息

Zisman A, Pantuck A J, Belldegrun A S

机构信息

University of California, School of Medicine, Department of Urology, Los Angeles 90095-1738, USA.

出版信息

Curr Urol Rep. 2001 Feb;2(1):55-61. doi: 10.1007/s11934-001-0026-8.

DOI:10.1007/s11934-001-0026-8

PMID:12084296

Abstract

The incidence of renal cell carcinoma (RCC) is rising steadily, but the ability to cure patients with metastatic RCC unfortunately remains limited. Emerging interest in gene therapy performance and safety is expressed by patients, medical institutes, and other agencies. It has become evident that better understanding of the genetic impairments and immune pathophysiology in RCC is essential for future improvement in patient care. Clinical trials now underway that are focusing on genetic and immune impairments will hopefully lead to future breakthroughs in RCC therapy. This paper reviews available gene therapies and other related therapeutic approaches for RCC and lists some of the current clinical trials focused on molecular-based therapies.

摘要

肾细胞癌（RCC）的发病率正在稳步上升，但不幸的是，治愈转移性RCC患者的能力仍然有限。患者、医疗机构和其他机构对基因治疗的性能和安全性的兴趣日益浓厚。显然，更好地了解RCC中的基因损伤和免疫病理生理学对于未来改善患者护理至关重要。目前正在进行的专注于基因和免疫损伤的临床试验有望在RCC治疗方面取得未来突破。本文综述了现有的RCC基因治疗和其他相关治疗方法，并列出了一些目前专注于分子疗法的临床试验。